Sonrotoclax vs Venetoclax
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: BCL-2 · full Acute Myeloid Leukemia pipeline
Sonrotoclax · Beqalzi
Marketed by BeOne Medicines
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07548710 (registry estimate)
No aligned efficacy figure on record for this race.
Venetoclax
Marketed by AbbVie and partners
NCT02993523 · Phase 3 · active, not recruiting
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial whose primary endpoint, overall survival, was met with a statistically significant improvement for venetoclax plus azacitidine. A power calculation was reported in the protocol and statistical analysis plan, and 431 participants were randomized against a planned 400.
Next expected readout: November 2026 · NCT03850574 (registry estimate)
Reported efficacy
Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) (missed)
Result source: NCT03069352
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sonrotoclax | Venetoclax |
|---|---|---|
| OS, median | —Not reported | —Not posted · NCT05654194 |
| Complete remission | —Not reported | 13.3%bNCT039419641 other result
|
| Event-free survival, median | —Not reported | 7.7 vs 11.2vs Venetoclax + AzacitidineNCT04266795 |
| Duration of response, median | —Not reported | —Not posted · NCT05654194 |
OS, median
- Sonrotoclax
- —Not reported
- Venetoclax
- —Not posted · NCT05654194
Complete remission
- Sonrotoclax
- —Not reported
- Venetoclax
- 13.3%bNCT03941964
1 other result
- 26.7% NCT03941964
Event-free survival, median
- Sonrotoclax
- —Not reported
- Venetoclax
- 7.7 vs 11.2vs Venetoclax + AzacitidineNCT04266795
Duration of response, median
- Sonrotoclax
- —Not reported
- Venetoclax
- —Not posted · NCT05654194
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Sonrotoclax: no structured comparison results are available for Acute Myeloid Leukemia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Sonrotoclax: 0 of 4 rows · Venetoclax: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Venetoclax |
|---|---|
| Dropout rate | n/a: no completion milestone400 mg + 20 mg/m^2a NCT04102020 · Phase 3 · registry result, not featured evidence · combination show 8 more resultsn/a: no completion milestone400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone400 mg + 200 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone400 mg + 300 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination 76.7%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 63.3%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04277442 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 4.3%400 mg + 20 mg/m^2a NCT04102020 · Phase 3 · registry result, not featured evidence · combination show 8 more results0%400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination 3.3%400 mg + 200 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 300 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination 3.3%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 26.7%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 22.9%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination — NCT04277442 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 21.7%400 mg + 20 mg/m^2a NCT04102020 · Phase 3 · registry result, not featured evidence · combination show 8 more results30.4%400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination 25%400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · registry result, not featured evidence · combination 16.7%400 mg + 200 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination 18.8%400 mg + 300 mg NCT04102020 · Phase 3 · registry result, not featured evidence · combination 63.3%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 73.3%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 76.5%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination 100% NCT04277442 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 400 mg + 20 mg/m^2a neutropenia 56.5% thrombocytopenia 34.8% diarrhoea 26.1% NCT04102020 · Phase 3 · registry result, not featured evidence · combination show 8 more results400 mg + 36 mg/m^2 neutropenia 69.6% thrombocytopenia 56.5% anaemia 34.8% NCT04102020 · Phase 3 · registry result, not featured evidence · combination 400 mg + 50 mg/m^2 neutropenia 80% thrombocytopenia 55% anaemia 35% NCT04102020 · Phase 3 · registry result, not featured evidence · combination 400 mg + 200 mg nausea 50% diarrhoea 43.3% neutropenia 33.3% NCT04102020 · Phase 3 · registry result, not featured evidence · combination 400 mg + 300 mg nausea 56.3% neutropenia 56.3% vomiting 56.3% NCT04102020 · Phase 3 · registry result, not featured evidence · combination 400 mg + 75 mg anaemia 76.7% neutrophil count decreased 63.3% nausea 56.7% NCT03941964 · Phase 3 · registry result, not featured evidence · combination 400 mg + 20 mg anaemia 80% platelet count decreased 53.3% white blood cell count decreased 53.3% NCT03941964 · Phase 3 · registry result, not featured evidence · combination 20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 neutropenia 58% thrombocytopenia 45.7% constipation 42% NCT04266795 · Phase 2 · registry result, not featured evidence · combination activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% alkaline phosphatase increased 100% NCT04277442 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Venetoclax
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Chronic Lymphocytic Leukemia
Shared mechanism: BCL-2 · full Chronic Lymphocytic Leukemia pipeline
Sonrotoclax · Beqalzi
Marketed by BeOne Medicines
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06637501 (registry estimate)
No aligned efficacy figure on record for this race.
Venetoclax
Marketed by AbbVie and partners
NCT02005471 · Phase 3 · completed
This randomized, open-label Phase 3 trial compared venetoclax plus rituximab with bendamustine plus rituximab in 389 patients with relapsed or refractory chronic lymphocytic leukaemia. The primary endpoint was progression-free survival as assessed by the investigator. Median progression-free survival was 54.7 months with venetoclax plus rituximab and 17.0 months with bendamustine plus rituximab (hazard ratio 0.23, 95% CI 0.18 to 0.29; p<0.0001). Neither patients nor investigators were masked to treatment, and progression was judged by the treating investigators.
Next expected readout: November 2026 · NCT04895436 (registry estimate)
Reported efficacy
Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death (Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)); Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines (Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)): Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) (met)
Result source: NCT02005471
Results for Chronic Lymphocytic Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Sonrotoclax: no structured comparison results are available for Chronic Lymphocytic Leukemia.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sonrotoclax's landscape · Venetoclax's landscape